{
    "id": 27867,
    "fullName": "STRN - NTRK2",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "STRN-NTRK2 results from the fusion of STRN and NTRK2 (PMID: 29606586). STRN-NTRK2 has been identified in mesenchymal tumors, soft tissue sarcoma and advanced solid tumors (PMID: 29683818, PMID: 29606586, PMID: 29466156), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                },
                {
                    "id": 11285,
                    "pubMedId": 29606586,
                    "title": "Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29606586"
                },
                {
                    "id": 14122,
                    "pubMedId": 29683818,
                    "title": "Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29683818"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6801,
        "geneSymbol": "STRN",
        "terms": [
            "STRN",
            "PPP2R6A",
            "SG2NA",
            "STRN1"
        ]
    },
    "variant": "STRN - NTRK2",
    "createDate": "04/26/2018",
    "updateDate": "10/01/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4915,
                "geneSymbol": "NTRK2",
                "terms": [
                    "NTRK2",
                    "EIEE58",
                    "GP145-TrkB",
                    "OBHD",
                    "trk-B",
                    "TRKB"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15293,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Vitrakvi (larotrectinib) treatment resulted in partial response in a pediatric patient with advanced solid tumor harboring a STRN-NTRK2 fusion (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 29440,
                "profileName": "STRN - NTRK2"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13814,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Vitrakvi (larotrectinib) treatment resulted in partial response in a pediatric patients with soft tissue sarcoma harboring STRN-NTRK2 fusion (PMID: 29606586; NCT02637687).",
            "molecularProfile": {
                "id": 29440,
                "profileName": "STRN - NTRK2"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1115,
                "name": "sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11285,
                    "pubMedId": 29606586,
                    "title": "Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29606586"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29440,
            "profileName": "STRN - NTRK2",
            "profileTreatmentApproaches": [
                {
                    "id": 19326,
                    "name": "Larotrectinib",
                    "profileName": "STRN - NTRK2"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}